Episode
Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig
- Podcast
- Business Of Biotech
- Published
- Sep 7, 2026
- Duration seconds
- 3359
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/funding-a-virtual-biotech-without-institutional-capital-with-sarcomatrix-s-david-craig/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/business-of-biotech-123501/funding-a-virtual-biotech-without-institutional-capital-with-sarcomatrix-s-david-craig.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, David Craig, Cofounder, President, and CEO at Sarcomatrix, explains why the old biotech playbook breaks down in today’s funding environment and what it takes to build a lean virtual drug development company without institutional financing. Craig describes practical financing paths, hard truths about costs, and the tradeoffs that make a rare disease program investable through alternative ...